Bafna Pharma Share Price

Bafna Pharmaceuticals Limited, with its corporate operations in Chennai, functions as a pharmaceutical formulation manufacturing company in India. The company was founded as a proprietorship concern in 1981 and is based in Tamil Nadu. Bafna Pharmaceuticals is primarily engaged in the manufacture of drugs and medicines and selling a reputed brand namely RARICAP. The company specializes in non-betalactam solid oral dosage forms and has 336 licensed pharmaceutical formulations. The company also offers contract research and manufacturing services (CRAMS) and technology transfers. It supplies to both domestic and international markets. 

Bafna Pharmaceuticals share price on NSE and BSE signifies how market participants react to the company’s operational performance and the overall developments in the generic pharmaceutical sector. The company’s financial health depends on production volumes of pharmaceutical formulations, price realizations for its branded products, capacity utilization of its manufacturing units, and the performance of its contract research and manufacturing services (CRAMS) segment. Bafna Pharmaceuticals stock price is influenced by various factors such as earnings, import duties on drug intermediates and APIs, regulatory changes from CDSCO, and global pharmaceutical demand for generic drugs. In the longer run, strategies such as expansion of manufacturing facilities, development of new therapeutic segments, and increasing penetration in regulated markets affect the stock market sentiments. All these factors need to be monitored closely to have an idea about the company’s stock price movements. 

Bafna Pharmaceuticals live share price provides real-time information about the last price traded, bid and ask prices, and volume traded. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the Bafna Pharmaceuticals live price helps in observing short term price volatility and shows how a stock moves relative to the broader pharmaceutical index. Furthermore, monitoring Bafna Pharmaceuticals stock price movements helps investors understand real-time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short-term performance, and respond to news, quarterly results, or sector trends that may influence the company’s valuation and overall investment outlook. 

Bafna Pharmaceuticals Limited Company Fundamentals 

A. Company Background

Bafna Pharmaceuticals Limited was founded as a proprietor concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical. The company was later converted to a public limited company and is now a subsidiary of SRJR Lifesciences LLP. The company is engaged in the business of manufacturing pharmaceutical formulations of Betalactum and Non Betalactum products. Its manufacturing operations are based in India, with a manufacturing unit set up at Madhavaram, Chennai, Tamil Nadu for manufacturing tablets, while corporate functions are managed from its administrative offices in Chennai, Tamil Nadu. The company has a manufacturing facility for tablets with an installed capacity and also manufactures 336 licensed pharmaceutical formulations, having globally registered 78 of its products. Over time, the company has expanded its production capacity and product portfolio to serve both domestic and export markets, including Europe, UK, Australia, Sri Lanka, Africa, Philippines, and Tanzania. Financial performance is assessed through standard metrics such as revenue growth, operating margins, and capacity utilisation. Market valuation indicators such as the P/E ratio are used by analysts for comparative assessment within the pharmaceutical manufacturing sector. Overall fundamentals are influenced by raw material availability (APIs), demand cycles in chronic and acute therapy segments, regulatory approvals, and API price fluctuations. 

B. Company Product Lines

• Pharmaceutical Finished Formulations 

• Engaged in the manufacture of finished dosage forms including tablets and capsules. 

• Non-Betalactam Solid Oral Dosage Forms 

• Specializes in non-betalactam solid oral dosage forms including tablets and capsules in various therapeutic areas. 

• RARICAP Brand Pharmaceuticals 

• Owns a reputed pharmaceutical brand RARICAP sold in markets. 

• Betalactam Formulations 

• Manufactures pharmaceutical formulations of Betalactum products. 

• Contract Research and Manufacturing Services (CRAMS) 

• Provides contract research and manufacturing services and technology transfers to third party clients. 

C. Company Revenue Model

• Domestic Formulation Sales 

• Revenue generated through sales of branded and generic pharmaceutical formulations to distributors, hospitals, and retailers across India. 

• Export Sales 

• Contribution from international customers in regulated markets like Europe, UK, Australia and generic markets in Africa, Sri Lanka, Philippines, Tanzania and Nigeria. 

• CRAMS Income 

• Revenue from contract research and manufacturing services provided to Indian and global pharmaceutical clients. 

• Technology Transfer Fees 

• Income from technology transfer services for manufacturing of pharmaceutical products. 

Revenue performance is primarily influenced by demand for pharmaceuticals in chronic segments, raw material sourcing, and price realizations in domestic and regulated export markets. 

D. Geographic Presence

• Corporate and Registered Office 

• Administrative and management functions based in Chennai, Tamil Nadu, India. 

• Manufacturing Facility 

• Primary production plant for tablets located at Madhavaram, Chennai, Tamil Nadu. 

• Distribution Network 

• Domestic distribution across India through pharmaceutical distributors and trade channels. 

• Export Markets 

• Products are supplied to Europe, United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, and Nigeria. 

E. Key Milestones

• 1981: Bafna Pharmaceuticals started as a proprietorship concern by Bafna Mahaveer Chand. 

• 1984: Setup of first manufacturing unit at Madhavaram for tablets with installed capacity. 

• 2008: Initial public offering (IPO) and listing of equity shares on stock exchanges with listing on June 27, 2008. 

• Recent years: Continued focus on exports to regulated markets and CRAMS business growth. 

F. Industry Perspective

The pharmaceutical formulation manufacturing industry is capital-intensive and closely linked to demand from healthcare institutions, prescription patterns, and access to medicines. Demand trends are influenced by disease prevalence, healthcare infrastructure spending, and generic drug adoption globally. The industry faces fluctuations in API prices, regulatory approvals from CDSCO and international agencies, and pricing pressure from government drug price control mechanisms. Environmental regulations and GMP compliance requirements are increasingly shaping production practices. Companies in this sector must manage regulatory compliance, supply chain logistics, and competition from domestic and multinational generic formulators. These factors collectively influence financial performance and investor perception of firms like Bafna Pharmaceuticals. 

Bafna Pharmaceuticals Limited Stock Market Presence: Listings and Index Representation 

Bafna Pharmaceuticals Limited is listed on the National Stock Exchange (NSE) under the symbol BAFNAPH and on the Bombay Stock Exchange (BSE) with the scrip code 532989. Bafna Pharmaceuticals share price is actively traded on both exchanges. The company’s market presence is within the small-cap segment of the market. Due to its size and sector focus, Bafna Pharmaceuticals stock price is generally tracked by investors interested in the generic pharmaceutical formulation and CRAMS industry. 

Bafna Pharmaceuticals Limited is part of several broad-based and sector-specific stock market indices, reflecting its position as a small-cap pharmaceutical company in India. While it is not included in benchmark indices like the Sensex or Nifty 50, it is a constituent of wider market indices such as the BSE SmallCap index and sector-specific pharmaceutical lists. Bafna Pharmaceuticals share price finds representation in these indices based on its market standing. This presence helps investors track the stock relative to other small-cap pharmaceutical and CRAMS companies. 

Bafna Pharmaceuticals Limited Stock Performance and Share Price History 

Bafna Pharmaceuticals share price on the stock exchanges reflects its position as a generic pharmaceutical formulation manufacturer with a presence in regulated and emerging markets. Its performance is qualitatively driven by factors such as regulatory approvals for new products, growth in exports to regulated markets, CRAMS business momentum, management of raw material (API) costs, the ability to control operational expenses, and product mix shifts towards high-margin branded generics. Investors compare Bafna Pharmaceuticals share price current movement with other small-cap pharmaceutical companies to assess relative strength. 

These underlying factors become visible through real market movements across different time periods. Similar trends appear during earnings-driven price changes. Broader sector strength has also supported the stock at various points. Beyond operational and sector influences, corporate actions—such as the company’s strategic focus on CRAMS services—have significantly affected Bafna Pharmaceuticals share price movements by shaping future growth expectations beyond its traditional manufacturing business. This shows how strategic initiatives may trigger short-term swings, even within a regulatory environment influenced by CDSCO approval cycles and API import dynamics. 

While short-term movements respond to events and announcements, longer-term valuation trends are better captured by Bafna Pharmaceuticals share price annual high and low levels, offering context beyond daily or weekly changes. A notable peak indicates stronger product offtake and stable API costs, whereas a significant low aligns with market corrections or sector volatility. These extremes reflect the impact of drug pricing policies, global API price trends, and earnings visibility, providing a framework for understanding historical performance. 

Bafna Pharmaceuticals share price behaviour mirrors the trading patterns of a small-cap generic pharmaceutical company within India’s formulation and CRAMS ecosystem. The company’s diversified portfolio spanning domestic generics, branded formulations, and CRAMS services has shaped its price history. Over the past several years, the stock has experienced periods of sharp gains followed by phases of consolidation. For instance, it delivered positive returns in certain periods when export approvals to regulated markets were announced, but recorded negative returns in other years, underperforming the broader small-cap index at times. Bafna Pharmaceuticals share price has shown higher volatility compared to the overall market at certain points. 

The company’s performance has closely tracked API price cycles, regulatory approvals, and export demand from regulated markets. Positive momentum in Bafna Pharmaceuticals share price appeared when the company secured approvals for new products in regulated markets and expanded its CRAMS client base, improving export realizations. However, periods of high API procurement costs, currency fluctuations impacting export margins, and competitive pressure from larger pharmaceutical companies in regulated markets have led to consolidation in Bafna Pharmaceuticals share price. Profitability has shown significant variability in recent quarters, primarily due to API cost volatility and regulatory inspection cycles impacting plant utilisation. 

Despite pandemic disruptions, Bafna Pharmaceuticals shares showed resilience during the recovery phase. While the broader pharmaceutical sector faced supply chain challenges, the company’s diversified product portfolio and established export base helped Bafna Pharmaceuticals share price recover from pandemic lows. The company maintains a workforce and exports to multiple regulated and semi-regulated markets globally. 

Bafna Pharmaceuticals share price has declined for several recurring reasons. A drop in export demand from key geographies directly impacts revenue and leads to selling pressure. Changes in government policy regarding drug price controls (NPPA) or import duties on APIs can also cause the stock to fall. Moreover, increases in operational costs (e.g., API procurement or energy expenses) without matching price increases squeeze margins, making the stock less attractive. Periods of global economic slowdown that affect healthcare spending in export markets raise concerns about order volumes, leading to price declines. The stock is sensitive to regulatory news; if the CDSCO issues warnings or import alerts, it can cause Bafna Pharmaceuticals share price to fall as investors adjust expectations for future growth. Broader market selloffs in small-cap stocks also pull Bafna Pharmaceuticals share price lower, regardless of the company’s individual performance. Lower capacity utilisation or reduced CRAMS business pipelines directly hurts revenue, resulting in a lower valuation. 

Bafna Pharmaceuticals Limited Investor Relevance and Role in Portfolio 

Bafna Pharmaceuticals Limited is a holding in small-cap and pharmaceutical sector portfolios, offering exposure to generic formulations, branded generics, and CRAMS services. Its inclusion in pharmaceutical indices underscores its importance in India’s generic drug manufacturing space with a niche in non-betalactam oral solids. The company’s position as an established formulation manufacturer with registered products in regulated markets, together with its CRAMS capabilities and diversified product mix, makes it a consideration for long-term allocations. 

Bafna Pharmaceuticals share price is influenced by the company’s ownership structure. Bafna Pharmaceuticals’ equity is held by a broad mix of promoters, institutional investors, and retail investors, reflecting its standing in India’s pharmaceutical sector. Promoters hold a stable majority stake of seventy-five percent, reflecting strong internal control. Promoter shareholding has remained largely stable across recent quarters. Foreign institutional investors and domestic institutional investors hold negligible or zero stakes. The public holds the remaining stake of twenty-five percent. The company’s board of directors includes representatives from the Bafna family. This investor base, with stable promoter participation, underscores the company’s role as a holding in both domestic and focused portfolios concentrating on the pharmaceutical sector. 

Beyond fundamentals and ownership, Bafna Pharmaceuticals stock price is actively monitored in cash market segments, where trading volumes and delivery patterns reflect expectations on API prices, regulatory approvals for new products, and policy actions affecting drug pricing and imports. The stock is available for trading on both major Indian exchanges, allowing investors to take positions based on their outlook for the pharmaceutical sector. Market participants watch these trading indicators to gauge sentiment around quarterly results and regulatory updates from CARMEL or CDSCO. 

Technical indicators provide additional insight into short-term momentum shifts in Bafna Pharmaceuticals share price. While these indicators are primarily used for near-term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. In the short term and weekly timeframe, the stock has exhibited price movements that correlate with broader pharmaceutical sector trends. Based on available data, Bafna Pharmaceuticals share price beta indicates moderate volatility compared to the broader market. The company’s debt to equity ratio reflects a moderate use of leverage. Return on equity and return on capital employed are at modest levels, and the company’s book value per share serves as a reference point for valuation. 

Overall, Bafna Pharmaceuticals stock price demonstrates moderate volatility compared to the broader market, with the stock generally considered to have average systematic risk. This makes it somewhat sensitive to broader market movements and sector-specific factors such as drug pricing, regulatory actions, and API cost cycles. 

Bafna Pharmaceuticals Limited Sectoral Relevance and Peer Positioning 

Bafna Pharmaceuticals Limited sector relevance stems from its four-decade presence in the generic pharmaceutical industry, its specialization in non-betalactam solid oral dosage forms and Betalactam formulations, its portfolio of 336 licensed pharmaceutical formulations with 78 globally registered products, its reputed brand RARICAP, its specific focus on Contract Research and Manufacturing Services (CRAMS) and technology transfers, its manufacturing facility located at Madhavaram in Chennai, and its export presence across Europe, the UK, Australia, Sri Lanka, Africa, Philippines, Tanzania, and Nigeria, establishing it as a focused small-cap pharmaceutical provider to both domestic and regulated international markets. Peer comparisons with generic formulation companies like Unichem Laboratories, Indoco Remedies, Strides Pharma Science, Sequent Scientific, and Granules India focus on formulation portfolio size, regulatory approvals in regulated markets, CRAMS revenue contribution, and product mix rather than short-term stock moves. These benchmarks help investors assess operational scale, GMP compliance, and geographic penetration. Institutional tracking of API pricing, CDSCO approvals, and trade policies further highlights Bafna Pharmaceuticals positioning within India’s broader pharmaceutical manufacturing market. 

Bafna Pharmaceuticals P/E ratio reflects how investors perceive the company’s earnings relative to its revenue streams from finished formulations, branded generics, and CRAMS services. Based on available data, the P/E ratio around 63 to 76 indicates a certain market perception. The company’s profit after tax increased in certain periods, showing improvement from past performance. Quarterly performance has shown sequential growth in select quarters. The company’s earnings before interest and taxes has reflected ongoing operational improvements. Overall, these changes highlight how market sentiment evolved alongside the company’s operational performance in the pharmaceutical sector. 

Alongside valuation, Bafna Pharmaceuticals earnings per share provide insight into the company’s operational performance and income generation from exports, domestic branded sales, and contract manufacturing. Based on available data, the company reported a basic EPS of around 1.76, showing variability across periods. The trailing twelve-month EPS stands at a moderate level. The company’s EPS for the last full fiscal year improved compared to prior fiscal years. The company has a face value of ₹10 per share and is promoted by the Bafna family. More recent quarterly performance suggests that EPS has shown responsiveness to product mix improvement and operational leverage. 

Bafna Pharmaceuticals market cap highlights its position as a small-cap player within India’s generic formulation sector. Based on recent data, the company’s market capitalization is around ₹220 to ₹300 crore range, moving in line with investor perceptions of its growth potential following export approvals. From earlier periods through more recent phases, market cap showed certain trends as the company expanded its registered product base and entered new geographies, followed by a significant correction. This pattern reflects investor confidence when new export contracts were announced, followed by contraction during periods of regulatory uncertainty or API cost pressure. 

Finally, Bafna Pharmaceuticals earnings trajectory demonstrates the impact of operational execution in a competitive industry. In recent fiscal periods, total income showed growth supported by core formulation and CRAMS business. Based on available data, the company’s revenue from operations increased in certain periods. Total income grew accordingly. Profit after tax improved significantly in recent years as operational efficiencies were realized and export realizations improved. Quarterly performance has shown instances of sequential growth. The company’s export sales have grown in recent fiscal years compared to prior periods. The company has faced headwinds from fluctuating API prices, competitive bidding for CRAMS contracts, and pricing pressure in regulated markets. However, the company continues to focus on expanding its registered product portfolio and building its CRAMS business for future growth. These developments illustrate the growth journey in the generic pharmaceutical industry and the company’s position within this sector. 

Bafna Pharmaceuticals market cap follows typical trends for small-cap generic drug companies. The company’s earnings have shown improvements in recent periods, with revenue performing better. Quarterly earnings have varied based on API cycles and export order flows. The earnings per share figure has shown recovery. The price-to-earnings multiple has varied, reflecting changing investor expectations about CRAMS business wins and export approvals. When export approvals for new products in regulated markets are announced, the multiple may expand, while regulatory delays or cost pressure cause contraction. 

Summary 

Bafna Pharmaceuticals Limited operates as a small-cap generic pharmaceutical formulation manufacturer with a four-decade operating history. The company markets branded generics, CRAMS services, and exports to regulated markets. Bafna Pharmaceuticals share price reflects investor assessment of API price cycles, export approvals, and CRAMS order book. The stock trades on both NSE and BSE within the small-cap segment. Operational performance depends on regulatory approvals and API sourcing, while Bafna Pharmaceuticals stock price movements are observed by market participants tracking the pharmaceutical and CRAMS sector.